Liquid pharmaceutical composition
The present invention relates to novel liquid pharmaceutical compositions of adalimumab, which include adalimumab or a biosimilar thereof, a citrate buffering agent/system such as sodium citrate/citric acid, and a sugar stabilizer such as trehalose. Such a combination of components furnishes formulations having a stability (e.g. on storage and when exposed to stress) which is comparable to or an improvement upon those known in the art, and with fewer ingredients. Such advances will help adalimumab treatments to become more widely available at lower cost, and prolong the viability of pre-loaded delivery devices (e.g. prefilled syringes) to reduce unnecessary waste of the drug.
1. An aqueous pharmaceutical composition comprising:
(a) 45-55 mg/mL adalimumab;
(b) 5-14 mM citrate buffer system;
(c) 100-250 mM sugar stabilizer selected from the group consisting of trehalose and sorbitol; and
(d) 0.05-1.5 mg/mL surfactant selected from the group consisting of polysorbate 80 and polysorbate 20;
wherein the composition:
has a pH between 5.0 and 6.0;
is free of phosphate buffering agents; and
is free of amino acids selected from the group consisting of arginine, lysine, and aspartic acid; and
comprises at most one sugar stabilizer.
2. The aqueous pharmaceutical composition of claim 1 , wherein the sugar stabiliser is present at a concentration of 100 to 210 mM.
3. The aqueous pharmaceutical composition of claim 1 , wherein the citrate buffering agent or citrate buffer system is present at a concentration of 10 mM.
4. The aqueous pharmaceutical composition of claim 1 , wherein the surfactant is present at a concentration of 0.5 to 1.1 mg/mL.
5. The aqueous pharmaceutical composition of claim 1 , wherein the sugar stabiliser is sorbitol.
6. The aqueous pharmaceutical composition of claim 1 , wherein the pH of the composition is from 5.0 to 5.4.
7. The aqueous pharmaceutical composition of claim 1 , wherein the surfactant is polysorbate 20.
8. The aqueous pharmaceutical composition of claim 1 , wherein the composition further comprises a histidine buffer.
9. The aqueous pharmaceutical composition of claim 1 , wherein the sugar stabilizer is present at a concentration of 100 to 150 mM.
10. The aqueous pharmaceutical composition of claim 1 , wherein the composition comprises a tonicifier which is the sugar stabilizer.
11. The aqueous pharmaceutical composition of claim 1 , wherein the composition comprises only a single tonicifier, which is the sugar stabilizer.
12. The aqueous pharmaceutical composition of claim 1 , wherein the composition is free of amino acids or is free of amino acids with the exception of histidine which may be present as a further buffer system.
13. The aqueous pharmaceutical composition of claim 1 , wherein the composition consists of:
(a) 45-55 mg/mL adalimumab;
(b) a citrate buffer system alone or in combination with a further buffer system, wherein the citrate buffer system is present in the composition at a concentration of 5-14 mM;
(c) 100-200 mM sorbitol;
(d) 0.05-1.5 mg/mL polysorbate 20; and
(e) water;
wherein the composition has a pH between 5.0 and 6.0.
14. The aqueous pharmaceutical composition of claim 1 , wherein the composition consists of:
(a) 50 mg/mL adalimumab;
(b) a citrate buffer system alone or in combination with a further buffer system, wherein the citrate buffer system is present in the composition at a concentration of 5-14 mM;
(c) 100-150 mM sorbitol;
(d) 0.5-1.1 mg/mL polysorbate 20; and
(e) water;
wherein the composition has a pH between 5.0 and 6.0.
15. The aqueous pharmaceutical composition of claim 1 , wherein the composition consists of:
(a) 50 mg/mL adalimumab;
(b) a citrate buffer system alone or in combination with a further buffer system, wherein the citrate buffer system is present in the composition at a concentration of 10 mM;
(c) 100-150 mM sorbitol;
(d) 0.5-1.1 mg/mL polysorbate 20; and
(e) water;
wherein the composition has a pH between 5.0 and 5.4.
16. The aqueous pharmaceutical composition of claim 1 , wherein the composition consists of:
(f) 45-55 mg/mL adalimumab;
(g) a citrate buffer system in combination with a histidine buffering agent or histidine buffer system, wherein the citrate buffer system is present in the composition at a concentration of 5-14 mM;
(h) 100-200 mM sorbitol;
(i) 0.05-1.5 mg/mL polysorbate 20; and
(j) water;
wherein the composition has a pH between 5.0 and 6.0.
17. The aqueous pharmaceutical composition of claim 1 , wherein the composition consists of:
(f) 50 mg/mL adalimumab;
(g) a citrate buffer system in combination with a histidine buffering agent or histidine buffer system, wherein the citrate buffer system is present in the composition at a concentration of 5-14 mM;
(h) 100-150 mM sorbitol;
(i) 0.5-1.1 mg/mL polysorbate 20′ and
(j) water;
wherein the composition has a pH between 5.0 and 6.0.
18. The aqueous pharmaceutical composition of claim 1 , wherein the composition consists of:
(f) 50 mg/mL adalimumab;
(g) a citrate buffer system in combination with a histidine buffering agent or histidine buffer system, wherein the citrate buffer system is present in the composition at a concentration of 10 mM;
(h) 100-150 mM sorbitol;
(i) 0.5-1.1 mg/mL polysorbate 20; and
(j) water;
wherein the composition has a pH between 5.0 and 5.4.
19. The aqueous pharmaceutical composition of claim 1 , wherein the composition comprises:
the citrate buffer system in a molar ratio of citrate buffer system to adalimumab of from 14:1 to 40:1;
the sugar stabilizer in a molar ratio of sugar stabilizer to adalimumab of from 290:1 to 860:1; and
the surfactant in a molar ratio of surfactant to adalimumab of from 1:35 to 3:1.